A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly (Q26999313)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

review article

1 reference

title

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

pneumococcal conjugate vaccine

7 March 2020

main subject

1 reference

S Dirmesropian

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J G Wood

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

1 reference

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

Human Vaccines & Immunotherapeutics

7 March 2020

published in

3 references

20 June 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

11

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

818-825

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 3.0 Unported

7 March 2020

copyright license

1 reference

Vaccines for preventing pneumococcal infection in adults

20 June 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Serotype replacement in disease after pneumococcal vaccination

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of community-acquired pneumonia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

An introduction to Markov modelling for economic evaluation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4514194

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

31 May 2018

1 reference

https://api.crossref.org/works/10.1080%2F21645515.2015.1011954

The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21645515.2015.1011954

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21645515.2015.1011954

Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21645515.2015.1011954

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21645515.2015.1011954

Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21645515.2015.1011954

The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21645515.2015.1011954

A Randomized Study Comparing Combined Pneumococcal Conjugate and Polysaccharide Vaccination Schedules in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21645515.2015.1011954

Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21645515.2015.1011954

Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?

21 January 2018

1 reference

12 December 2020

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)

1 reference

12 December 2020

Economic evaluation of vaccination programs: the impact of herd-immunity

1 reference

12 December 2020

Immunological responses to pneumococcal vaccine in frail older people

1 reference

12 December 2020

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

1 reference

12 December 2020

10.1080/21645515.2015.1011954

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933180%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

PubMed publication ID

2 references